Brian M. Morrissey, M.D.
Professor, Division of Clinical Internal Medicine
Director, Cystic Fibrosis Center
Director, Pulmonary and Critical Care Fellowship
Chief, VA Northern California Health System
Site Director, VA Pulmonary Fellowship
To see if Brian M. Morrissey is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Medical Group - Sacramento (J Street)
Pulmonary, Critical Care and Sleep Medicine
2825 J St.
Sacramento, CA 95816
Phone: 916-734-8230
Fax: 916-734-4582
Clinical Interests
Dr. Morrissey has extensive experience managing patients with cystic fibrosis and bronchiectasis. He is skilled at performing a wide range of technically difficult procedures, including double-lumen intubation, whole-lung lavage and brachyradiation catheter placement. Dr. Morrissey's research focuses on airway disease and cystic fibrosis. He is studying the influence of oxidation on the pulmonary pathology of patients with cystic fibrosis.
Division
Pulmonary, Critical Care, and Sleep Medicine
Center/Program Affiliation
Undergraduate School
B.S., Yale University, New Haven CT 1986
Medical School
M.D., St. Louis University School of Medicine, St. Louis MO 1993
Internship
Internal Medicine, UC Davis Medical Center, Sacramento CA 1993-1994
Residency
Internal Medicine, UC Davis Medical Center, Sacramento CA 1994-1996
Fellowship
Internal Medicine, University of Colorado Health Sciences Center and National Jewish Medical and Research Center, Denver CO 1997-2000
In recognition of outstanding contributions in the mission area of clinical care, 2015
In recognition and appreciation for your skills, dedication and delivery of outstanding patient, 2015
Employee Excellence Award, 2011, 2012
Cystic Fibrosis Foundation Third Year Fellowship Grant, 1999
Cystic Fibrosis Foundation Second Year Fellowship Grant, 1998
Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C, Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Roque-Guerrero L, Acloque G, Aazami H, Cannon K, Simón-Campos JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021 Dec 2;385(23):e81. doi:10.1056/NEJMoa2108163. Epub 2021 Sep 29. PMID:34587383.
Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA; STOP2 Investigators. A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. Am J Respir Crit Care Med. 2021 Dec 1;204(11):1295-1305. doi:10.1164/rccm.202102-0461OC. PMID:34469706.
Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021 Aug 26;385(9):815-825. doi:10.1056/NEJMoa2100665. PMID:34437784.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 Jul;9(7):733-746. doi:10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Erratum in: Lancet Respir Med. 2021 Apr;9(4):e38. PMID:33581080.
Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, O'Donnell AE, Sullivan EJ, Mange KC, Fernandez C, Zou J, Daley CL; WILLOW Investigators. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med. 2020 Nov 26;383(22):2127-2137. doi:10.1056/NEJMoa2021713. Epub 2020 Sep 7. PMID:32897034.
Hauschildt KE, Seigworth C, Kamphuis LA, Hough CL, Moss M, McPeake JM, Iwashyna TJ; National Heart, Lung, and Blood Institute (NHLBI) Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. Financial Toxicity After Acute Respiratory Distress Syndrome: A National Qualitative Cohort Study. Crit Care Med. 2020 Aug;48(8):1103-1110. doi:10.1097/CCM.0000000000004378. PMID:32697479.
Dransfield MT, Garner JL, Bhatt SP, Slebos DJ, Klooster K, Sciurba FC, Shah PL, Marchetti NT, Sue RD, Wright S, Rivas-Perez H, Wiese TA, Wahidi MM, Goulart de Oliveira H, Armstrong B, Radhakrishnan S, Shargill NS, Criner GJ; LIBERATE Study Group:. Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial. Ann Am Thorac Soc. 2020 Jul;17(7):829-838. doi:10.1513/AnnalsATS.201909-666OC. PMID:32223724.
Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi:10.1056/NEJMoa1908639. Epub 2019 Oct 31. PMID:31697873.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi:10.1056/NEJMoa1903076. Epub 2019 May 20. PMID:31112379.